Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) to a sell rating in a research note issued to investors on Monday morning. Other equities analysts also recently issued research reports about the stock. JMP Securities increased their price target on shares of Madrigal Pharmaceuticals from $381.00 to $385.00 and gave the company a […]

Leave a Reply

Your email address will not be published.

Previous post Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Rating Upgraded by Leerink Partnrs
Next post AxoGen (NASDAQ:AXGN) Downgraded by StockNews.com